LLY vs ABBV stock comparison
ELI LILLY & Co vs. AbbVie · data as of November 13, 2026
ELI LILLY & Co (LLY) has a market value of about $1.36T, AbbVie (ABBV) about $521.5B. Over their latest twelve months ELI LILLY & Co had revenue of $86.5B and AbbVie $66.0B.
On our five checks ELI LILLY & Co scores higher: 3.4 out of 5 (good) against 1.8 (weak).
By area, the stronger company is ELI LILLY & Co on future growth; ELI LILLY & Co on track record; ELI LILLY & Co on financial health.
ELI LILLY & Co is cheaper on earnings (P/E 46.9 vs. 50.8).
ELI LILLY & Co leads on 14 of the compared lines and AbbVie on 8.
Side by side
| LLY | ABBV | |
|---|---|---|
| Size and price | ||
| Market cap | $1.36T | $521.5B |
| Share price | $1,443.50 | $295.03 |
| Score | ||
| Overall score (of 5) | 3.4 | 1.8 |
| Value | 0 | 0 |
| Future growth | 5 | 1 |
| Track record | 5 | 2 |
| Financial health | 3 | 2 |
| Shareholder returns | 4 | 4 |
| Valuation | ||
| P/E (TTM) | 46.9 | 50.8 |
| Forward P/E | 30.4 | 19.1 |
| Price / free cash flow | 69.1 | 27.6 |
| Price / sales | 15.7 | 7.9 |
| EV / EBITDA | 37.1 | 19.8 |
| PEG | 1.70 | — |
| DCF value vs. price | −37% | −20% |
| Business | ||
| Revenue | $86.5B | $66.0B |
| Net income | $27.6B | $10.3B |
| Free cash flow | $19.7B | $18.9B |
| Net margin | 31.9% | 15.7% |
| Gross margin (5-yr avg.) | 78.9% | 68.3% |
| ROIC (5-yr avg.) | 22.9% | 15.3% |
| Growth | ||
| Revenue growth (1 yr) | 44.7% | 8.6% |
| Revenue growth (5 yrs, per year) | 21.6% | 5.9% |
| EPS growth (5 yrs, per year) | 27.6% | -2.8% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$44.6B | -$61.5B |
| Dividend yield | 0.48% | 2.35% |
| Shareholder yield | 0.8% | 2.5% |
| Analysts | ||
| Upside to average target | +1% | +6% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: LLY TTM to September 30, 2026, ABBV TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, ELI LILLY & Co or AbbVie?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) ELI LILLY & Co scores 3.4 out of 5 and AbbVie 1.8; the table shows where each one is stronger.
Is ELI LILLY & Co cheaper than AbbVie?
On trailing earnings, ELI LILLY & Co trades at a P/E of 46.9 and AbbVie at 50.8, so ELI LILLY & Co is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, ELI LILLY & Co or AbbVie?
Over five years ELI LILLY & Co grew revenue about 21.6% a year and AbbVie about 5.9% a year.
Which pays a higher dividend?
ELI LILLY & Co yields 0.48% and AbbVie 2.35%.
Full ELI LILLY & Co analysis → Full AbbVie analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.